Xilio Therapeutics to Present Updated Phase 2 Data for Vilastobart, a Tumor-Activated, Fc-Enhanced Anti-CTLA-4, in Combination with Atezolizumab in Patients with Microsatellite Stable Colorectal Cancer at the 2025 ASCO Annual Meeting
Xilio Therapeutics (Nasdaq: XLO) has announced it will present updated Phase 2 clinical trial data for vilastobart (XTX101) at the 2025 ASCO Annual Meeting. The presentation will focus on the combination therapy of vilastobart, a tumor-activated, Fc-enhanced anti-CTLA-4 monoclonal antibody, with atezolizumab (Tecentriq®) in patients with metastatic microsatellite stable colorectal cancer (MSS CRC).
The data presentation is scheduled for Saturday, May 31, 2025, from 9:00 a.m. to 12:00 p.m. CDT during the Gastrointestinal Cancer - Colorectal and Anal poster session at the conference in Chicago, Illinois. The abstract ID is 3553 and will be displayed on Poster Board 222.
Xilio Therapeutics (Nasdaq: XLO) ha annunciato che presenterà dati aggiornati della fase 2 della sperimentazione clinica per vilastobart (XTX101) al congresso annuale ASCO 2025. La presentazione si concentrerà sulla terapia combinata di vilastobart, un anticorpo monoclonale anti-CTLA-4 attivato dal tumore e potenziato Fc, con atezolizumab (Tecentriq®) in pazienti con carcinoma colorettale metastatico microsatellite stabile (MSS CRC).
La presentazione dei dati è prevista per sabato 31 maggio 2025, dalle 9:00 alle 12:00 CDT, durante la sessione poster sul cancro gastrointestinale - colorettale e anale, che si terrà a Chicago, Illinois. L'ID dell'abstract è 3553 e sarà esposto sul Poster Board 222.
Xilio Therapeutics (Nasdaq: XLO) ha anunciado que presentará datos actualizados del ensayo clínico de fase 2 para vilastobart (XTX101) en la Reunión Anual ASCO 2025. La presentación se centrará en la terapia combinada de vilastobart, un anticuerpo monoclonal anti-CTLA-4 activado por tumor y mejorado con Fc, junto con atezolizumab (Tecentriq®) en pacientes con cáncer colorrectal metastásico estable de microsatélites (MSS CRC).
La presentación de datos está programada para el sábado 31 de mayo de 2025, de 9:00 a.m. a 12:00 p.m. CDT durante la sesión de pósters sobre cáncer gastrointestinal - colorrectal y anal en la conferencia en Chicago, Illinois. El ID del resumen es 3553 y se mostrará en el Poster Board 222.
Xilio Therapeutics (나스닥: XLO)는 2025년 ASCO 연례회의에서 빌라스토바트(XTX101)의 2상 임상시험 데이터 업데이트를 발표할 예정입니다. 발표는 종양 활성화 및 Fc 강화된 항-CTLA-4 단클론 항체인 빌라스토바트와 아테졸리주맙(Tecentriq®)의 병용 요법에 대해, 전이성 마이크로새틀라이트 안정 대장암(MSS CRC) 환자를 대상으로 진행됩니다.
데이터 발표는 2025년 5월 31일 토요일 오전 9시부터 12시까지 CDT 시간에 일리노이주 시카고에서 열리는 위장관암 - 대장 및 항문 포스터 세션에서 예정되어 있습니다. 초록 ID는 3553이며 포스터 보드 222에 게시됩니다.
Xilio Therapeutics (Nasdaq : XLO) a annoncé qu'elle présentera des données mises à jour de l'essai clinique de phase 2 pour vilastobart (XTX101) lors de la réunion annuelle ASCO 2025. La présentation portera sur la thérapie combinée de vilastobart, un anticorps monoclonal anti-CTLA-4 activé par la tumeur et amélioré Fc, avec atezolizumab (Tecentriq®) chez des patients atteints de cancer colorectal métastatique stable au niveau des microsatellites (MSS CRC).
La présentation des données est prévue le samedi 31 mai 2025, de 9h00 à 12h00 CDT, lors de la session poster sur le cancer gastro-intestinal - colorectal et anal, à la conférence de Chicago, Illinois. L'ID du résumé est 3553 et sera affiché sur le Poster Board 222.
Xilio Therapeutics (Nasdaq: XLO) hat angekündigt, aktualisierte Daten der Phase-2-Studie zu Vilastobart (XTX101) auf dem ASCO-Jahrestreffen 2025 zu präsentieren. Die Präsentation konzentriert sich auf die Kombinationstherapie von Vilastobart, einem tumoraktivierten, Fc-verbesserten Anti-CTLA-4 monoklonalen Antikörper, mit Atezolizumab (Tecentriq®) bei Patienten mit metastasiertem mikrosatellitenstabilem kolorektalem Krebs (MSS CRC).
Die Datenpräsentation ist für Samstag, den 31. Mai 2025, von 9:00 bis 12:00 Uhr CDT während der Poster-Session zu gastrointestinalen Tumoren – Kolorektal und Anal auf der Konferenz in Chicago, Illinois, geplant. Die Abstract-ID lautet 3553 und wird am Poster Board 222 gezeigt.
- None.
- None.
WALTHAM, Mass., April 23, 2025 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living with cancer, today announced plans to present updated data from its ongoing Phase 2 clinical trial investigating vilastobart, a tumor-activated, Fc-enhanced anti-CTLA-4, in combination with atezolizumab (Tecentriq®) in patients with metastatic microsatellite stable colorectal cancer (MSS CRC) at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting. The conference is being held in Chicago, Illinois from May 30 to June 3, 2025.
Presentation Details
Title: Vilastobart (XTX101), a tumor-activated, Fc-enhanced anti-CTLA-4 monoclonal antibody, in combination with atezolizumab in patients with MSS CRC
Abstract ID: 3553
Poster Session: Gastrointestinal Cancer - Colorectal and Anal
Poster Board: 222
Session Date and Time: Saturday, May 31, from 9:00 a.m. to 12:00 p.m. CDT
About Vilastobart and the Phase 1/2 Combination Clinical Trial
Vilastobart is an investigational tumor-activated, Fc-enhanced, high affinity binding anti-CTLA-4 monoclonal antibody designed to block CTLA-4 and deplete regulatory T cells when activated in the tumor microenvironment (TME). In 2023, Xilio entered into a co-funded clinical trial collaboration with Roche to evaluate vilastobart in combination with atezolizumab (Tecentriq®) in a multi-center, open-label Phase 1/2 clinical trial. Xilio is currently evaluating the safety of the combination in Phase 1C dose escalation in patients with advanced solid tumors and the safety and efficacy of the combination in Phase 2 in patients with metastatic microsatellite stable colorectal cancer with and without liver metastases. Please refer to NCT04896697 on www.clinicaltrials.gov for additional details.
About Xilio Therapeutics
Xilio Therapeutics is a clinical-stage biotechnology company discovering and developing tumor-activated, or masked, immuno-oncology (I-O) therapies with the goal of significantly improving outcomes for people living with cancer without the systemic side effects of current I-O treatments. The company is leveraging its proprietary platform to advance a pipeline of novel, tumor-activated I-O molecules that are designed to optimize the therapeutic index by localizing anti-tumor activity within the tumor microenvironment. Learn more by visiting www.xiliotx.com and follow us on LinkedIn (Xilio Therapeutics, Inc.).
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, statements regarding plans to present clinical data from the Phase 2 clinical trial for vilastobart in combination with atezolizumab in patients with metastatic MSS CRC; and Xilio’s strategy, goals, business plans and focus. The words “aim,” “may,” “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “seek,” “target” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release are based on management’s current expectations and beliefs and are subject to a number of important risks, uncertainties and other factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, general market conditions; risks and uncertainties related to ongoing and planned research and development activities, including initiating, conducting or completing preclinical studies and clinical trials and the timing and results of such preclinical studies or clinical trials; the delay of any current or planned preclinical studies or clinical trials or the development of Xilio’s current or future product candidates; Xilio’s ability to obtain and maintain sufficient preclinical and clinical supply of current or future product candidates; Xilio’s advancement of multiple early-stage immune cell engager programs; interim or preliminary preclinical or clinical data or results, which may not be replicated in or predictive of future preclinical or clinical data or results; Xilio’s ability to successfully demonstrate the safety and efficacy of its product candidates and gain approval of its product candidates on a timely basis, if at all; results from preclinical studies or clinical trials for Xilio’s product candidates, which may not support further development of such product candidates; actions of regulatory agencies, which may affect the initiation, timing and progress of current or future clinical trials; Xilio’s ability to obtain, maintain and enforce patent and other intellectual property protection for current or future product candidates; Xilio’s ability to obtain and maintain sufficient cash resources to fund its operations; the impact of international trade policies on Xilio’s business, including U.S. and China trade policies; Xilio’s ability to maintain its clinical trial collaboration with Roche to develop vilastobart in combination with atezolizumab; and Xilio’s ability to maintain its collaboration and partnership agreements with Gilead and AbbVie. These and other risks and uncertainties are described in greater detail in the sections entitled “Risk Factor Summary” and “Risk Factors” in Xilio’s filings with the U.S. Securities and Exchange Commission (SEC), including Xilio’s most recent Annual Report on Form 10-K and any other filings that Xilio has made or may make with the SEC in the future. Any forward-looking statements contained in this press release represent Xilio’s views only as of the date hereof and should not be relied upon as representing its views as of any subsequent date. Except as required by law, Xilio explicitly disclaims any obligation to update any forward-looking statements.
This press release contains hyperlinks to information that is not deemed to be incorporated by reference in this press release.
TECENTRIQ is a registered trademark of Genentech USA, Inc., a member of the Roche Group.
Investor and Media Contact
Scott Young
Vice President, Investor Relations and Corporate Communications
investors@xiliotx.com
FAQ
What is the purpose of Xilio Therapeutics' Phase 2 trial for vilastobart (XLO)?
When will XLO present its Phase 2 data for vilastobart at ASCO 2025?
What type of cancer is XLO's vilastobart targeting in the Phase 2 trial?
How does vilastobart work in cancer treatment?
